...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Digestive Diseases and Sciences >Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
【24h】

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

机译：乙型肝炎表面抗原损失与替诺福韦解毒型富马酸盐加上Peginterferon Alfa-2a：第120周分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and AimsHepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during oral antiviral treatment. A current unmet need in CHB management is achievement of HBsAg loss with a finite course of oral antiviral therapy, thereby allowing discontinuation of treatment. Significantly higher rates of HBsAg loss at 72weeks post-treatment have been demonstrated when tenofovir disoproxil fumarate (TDF) was combined with pegylated interferon (PEG-IFN) for 48weeks compared with either monotherapy. This analysis provides follow-up data at week 120.MethodsIn an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus PEG-IFN for 48weeks (group A), TDF plus PEG-IFN for 16weeks followed by TDF for 32weeks (group B), TDF for 120weeks (group C), or PEG-IFN for 48weeks (group D). Efficacy and safety at week 120 were assessed.ResultsRates of HBsAg loss at week 120 were significantly higher in group A (10.4%) than in group B (3.5%), group C (0%), and group D (3.5%). Rates of HBsAg loss and HBsAg seroconversion in group A were significantly higher than rates in group C (P0.001 for both) or group D (HBsAg loss: P=0.002; HBsAg seroconversion: P0.001).ConclusionsThe results of this analysis confirm the results from earlier time points which demonstrate the increased rate of HBsAg loss in patients treated with a finite course of PEG-IFN plus TDF compared with the rates in patients receiving either monotherapy.
机译：背景和AIMSHEPTETISB表面抗原（HBSAG）损失是理想的临床终点，但在口腔抗病毒治疗期间很少实现。 CHB管理中的目前未满足的需求是通过有限的口腔抗病毒治疗方法实现HBsAg损失，从而允许停止治疗。当与单一疗法相比，当替诺福韦毒性富马酸薄荷酸酯（TDF）与聚乙二醇化干扰素（PEG-IFN）结合48周时，已经证明了72周的HBsAg损失率显着提高了72周的损失。该分析在第120周提供后续数据。方法是一个开放标签，有效控制的研究，740例慢性乙型肝炎患者被随机分配到48周（A），TDF Plus PEG-IFN的TDF Plus PEG-IFN对于16周，其次是32周（B组），120周（C组）的TDF（C组），或48周的PEG-IFN（D组）。第120周的疗效和安全得到评估。第120周的HBsAg损失的培养物（10.4％）显着高于B（3.5％），C组（0％）和D组（3.5％）。 A组HBsAg损失和HBsAg血清转化率的速率显着高于C组（P <0.001）或群D的速率（HBsAg损失：P = 0.002; HBsAg Seroconversion：P <0.001）。该分析的结果确认该分析的结果确认早期时间点的结果证明了用PEG-IFN Plus TDF治疗的患者的HBsAg损失率增加，与接受单一疗法的患者的速率相比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号